After 12 months of follow-up, patients who received drug-eluting stents had a 3.1% rate of major adverse coronary events, including a 2.4% rate of target lesion revascularization. Among the patients who received bare-metal stents the major adverse event rate was 30.2%, including a 29.6% rate of revascularization. The rate of stent thrombosis was 0.6% in patients who received drug-eluting stents, compared with a 3.1% rate among those treated with bare-metal stents.
